Welcome to the international HTA database

Showing [23734 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2006	Medical Services Advisory Committee (MSAC)	Review of current practices and future directions in the diagnosis, prevention and treatment of lymphoedema in Australia: report to the Australian Health Ministers' Advisory Council February 2004
2023	Adelaide Health Technology Assessment (AHTA)	Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
2020	Health Information and Quality Authority (HIQA)	Review of guidance for the operation of emergency medical dispatch centres in the context of COVID-19 and beyond
2004	NIHR Health Technology Assessment programme	Review of guidelines for good practice in decision-analytic modelling in health technology assessment
2005	Alberta Heritage Foundation for Medical Research (AHFMR)	Review of Health Technology Assessment products 2003 - 2004
2003	Alberta Heritage Foundation for Medical Research (AHFMR)	Review of health technology assessment skills development program
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for chronic inflammatory demyelinating polyneuropathy
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2011	Medical Services Advisory Committee (MSAC)	Review of interim funded service: Artificial intervertebral disc replacement - lumbar
2014	Medical Services Advisory Committee (MSAC)	Review of interim funded service: breast Magnetic Resonance Imaging (MRI)
2011	Medical Services Advisory Committee (MSAC)	Review of interim funded service: Hyperbaric Oxygen Therapy (HBOT) for the treatment of chronic non-diabetic wounds and non-neurological soft tissue radiation injuries
2011	Adelaide Health Technology Assessment (AHTA)	Review of interim funded service: vertebroplasty and new review of kyphoplasty
2021	Health Information and Quality Authority (HIQA)	Review of international ethics frameworks used in policy-making in the context of screening
2020	Health Information and Quality Authority (HIQA)	Review of international public policy responses to easing restrictions introduced to limit the spread of COVID-19
2011	Medical Services Advisory Committee (MSAC)	Review of kyphoplasty for the treatment of vertebral compression fracture and review of interim funded service: vertebroplasty for the treatment of vertebral compression fracture
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Review of luteinizing hormone-releasing hormone agonists in non-adjuvant therapy for advanced prostate cancer
1997	Australian Health Technology Advisory Committee (AHTAC)	Review of magnetic resonance imaging - systematic review
1996	Australian Health Technology Advisory Committee (AHTAC)	Review of magnetic resonance imaging (MRI)
2011	Adelaide Health Technology Assessment (AHTA)	Review of MBS items for specific ophthalmology services under the MBS Quality Framework (Stage I)
2012	Adelaide Health Technology Assessment (AHTA)	Review of MBS Items for specific ophthalmology services under the MBS Quality Framework (stage II)
2011	Medical Services Advisory Committee (MSAC)	Review of MBS Items for specific ophthalmology services under the MBS Quality Framework Stage 1
2009	Health Services Assessment Collaboration (HSAC)	Review of national and international clinical practice guidelines for the management of Borderline Personality Disorder: a systematic review.
2023	Health Information and Quality Authority (HIQA)	Review of national public health strategies in selected countries
2024	Health Information and Quality Authority (HIQA)	Review of national rare disease strategies in selected countries
2027	Belgian Health Care Knowledge Centre (KCE)	Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2002	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	Review of non-randomised mammographic screening programmes - Systematic review
1997	Australian Health Technology Advisory Committee (AHTAC)	Review of nucleic acid amplification technology
1997	Australian Health Technology Advisory Committee (AHTAC)	Review of nucleic acid amplification technology - systematic review
2003	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Review of primary care interventions to improve the quality of chronic disease management. IPE-03/39 (Public report)
2021	Health Information and Quality Authority (HIQA)	Review of processes in use to inform the expansion of newborn bloodspot screening programmes
2004	New Zealand Health Technology Assessment (NZHTA)	Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer
2006	New Zealand Health Technology Assessment (NZHTA)	Review of the National Cervical Screening programme. Chapter 5: interim operational policy and quality standards 2000. Technical brief.
1995	University of York	Review of the research on the effectiveness of health service interventions to reduce variations in health
1996	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Review of the scientific evidence of commercial products based on electromagnetic fields
1998	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Review of the scientific evidence of the clinical and economic implications of resistance of enterococcus to vancomycin
2009	Agency for Healthcare Research and Quality (AHRQ)	Reviews of selected pharmacogenetic tests for non-cancer and cancer conditions
2014	HAYES, Inc.	Revisional surgery for treatment of complications after bariatric surgery
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Revivent™ for heart failure with left ventricular scar
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Reza Band® for laryngopharyngeal reflux
2020	National Institute for Health and Care Excellence (NICE)	Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE medical technologies guidance 49
2021	Malaysian Health Technology Assessment (MaHTAS)	Rezūm therapy for management of benign prostatic hyperplasia
2000	Alberta Heritage Foundation for Medical Research (AHFMR)	RF tonsillar ablation
2010	NIHR Horizon Scanning Centre (NIHR HSC)	RG7204 for BRAF V600E mutation positive metastatic malignant melanoma - first or second line
2016	NIHR Horizon Scanning Centre (NIHR HSC)	RGN-259 for neurotrophic keratopathy
2008	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review
2015	Institute of Health Economics (IHE)	Rheumatoid arthritis in a policy perspective: a registry for research and better treatment of Albertans
2010	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	RhinoChill intra-nasal cooling system
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Rhinochill intranasal cooling device for protective cooling the brain after a cerebral ischaemic event
2015	NIHR Horizon Scanning Centre (NIHR HSC)	rhNGF for neurotrophic keratitis – first line
2016	NIHR Horizon Scanning Centre (NIHR HSC)	rhPTH (Natpar) for hypoparathyroidism – adjunctive therapy
2010	Institute for Clinical and Economic Review (ICER)	Rhythm control and stroke prevention strategies for patients with atrial fibrillation
2003	Institute for Clinical Systems Improvement (ICSI)	Rhythm therapy versus rate control for long-term management of recurrent atrial fibrillation
2015	NIHR Horizon Scanning Centre (NIHR HSC)	RhythmView™ system for cardiac arrhythmias
1999	Scottish Health Purchasing Information Centre (SHPIC)	Ribavirin and interferon alfa in chronic hepatitis C - an update
2002	Scottish Health Purchasing Information Centre (SHPIC)	Ribavirin and interferon alfa in the treatment of chronic hepatitis C
2000	University HealthSystem Consortium (UHC)	Ribavirin/interferon alfa 2b
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib for advanced hormone receptor positive, HER2 negative breast cancer – first line
2017	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer
2017	National Institute for Health and Care Excellence (NICE)	Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 496
2021	National Institute for Health and Care Excellence (NICE)	Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 687
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib with tamoxifen and goserelin, or a non-steroidal aromatase inhibitor and goserelin - breast cancer: advanced; hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative; premenopausal women – first line
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Ridaforolimus for unresectable locally advanced and metastatic soft tissue and bone sarcoma - maintenance therapy
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rifaximin (Xifaxanta®)
2015	National Institute for Health and Care Excellence (NICE)	Rifaximin for preventing episodes of overt hepatic encephalopathy. NICE technology appraisal guidance 337
2019	Agency for Care Effectiveness (ACE)	Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2015	NIHR Health Services and Delivery Research programme	Right cot, right place, right time: improving the design and organisation of neonatal care networks – a computer simulation study
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Rigosertib for higher risk myelodysplastic syndromes – second and subsequent line
2009	NIHR Horizon Scanning Centre (NIHR HSC)	Rilonacept for cryopyrin associated periodic syndromes
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Rilonacept for gout
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rilpivirine (Edurant®)
1997	Wessex Institute for Health Research and Development (WIHRD)	Riluzole for motor neurone disease
1996	Scottish Health Purchasing Information Centre (SHPIC)	Riluzole for motor neurone disease. Briefing note
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Riluzole for the treatment of amyotryophic lateral sclerosis: an assessment of clinical efficacy and safety
2023	National Institute for Health and Care Excellence (NICE)	Rimegepant for preventing migraine. NICE technology appraisal guidance 906
2023	National Institute for Health and Care Excellence (NICE)	Rimegepant for treating migraine. NICE technology appraisal guidance 919
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Rimonabant (Acomplia) for type 2 diabetes
2004	NIHR Horizon Scanning Centre (NIHR HSC)	Rimonabant for smoking cessation, weight loss and cardiovascular risk factors of overweight/obesity - horizon scanning review
2009	NIHR Health Technology Assessment programme	Rimonabant for the treatment of overweight and obese people
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Rindopepimut for EGFRvIII positive glioblastoma multiforme - first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Riociguat (Adempas®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Riociguat (Adempas®)
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Riociguat for the treatment of pulmonary hypertension
2023	National Institute for Health and Care Excellence (NICE)	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023	National Institute for Health and Care Excellence (NICE)	Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2022	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2019	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 596
2024	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 998
2021	National Institute for Health and Care Excellence (NICE)	Risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 755
2013	NIHR Health Technology Assessment programme	Risk Adjustment In Neurocritical care (RAIN) - prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study
2007	Andalusian Health Technology Assessment Area (AETSA)	Risk adjustment systems in health services assessment
2001	Health Council of the Netherlands Gezondheidsraad (GR)	Risk assessment of DON (deoxynivanol) in grain products - systematic review, expert panel
1995	Health Council of the Netherlands Gezondheidsraad (GR)	Risk assessment of manual lifting
2008	Institute of Health Economics (IHE)	Risk assessment tools for predicting recidivism of spousal violence
2014	Agency for Healthcare Research and Quality (AHRQ)	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. preventive services task force recommendation
2020	NIHR Health Technology Assessment programme	Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2007	New Zealand Health Technology Assessment (NZHTA)	Risk factors for breast cancer in women: a systematic review of the literature